Logo

INBS

Intelligent Bio Solutions Inc.

INBS

Intelligent Bio Solutions Inc. • NASDAQ
$0.66 ▼ -1.58% (-0.01)
Market Cap $4.26 M
52w High $2.75
52w Low $0.64
Dividend Yield 0%
P/E -0.4
Volume 38.60K
Outstanding Shares 6.45M

Income Statement

Period Revenue Operating Expense Net Income Net Profit Margin Earnings Per Share EBITDA
Q1-2026 $1.112M ▲ $3.518M ▲ $-2.983M ▲ -268.305% ▲ $-0.35 ▲ $-2.676M ▲
Q4-2025 $843.884K ▲ $3.437M ▲ $-3.09M ▼ -366.132% ▼ $-0.44 $-2.792M ▼
Q3-2025 $728.867K ▲ $2.895M ▲ $-2.544M ▼ -348.97% ▲ $-0.44 ▲ $-2.234M ▼
Q2-2025 $607.494K ▼ $2.488M ▼ $-2.249M ▲ -370.287% ▼ $-0.5 ▲ $-1.936M ▲
Q1-2025 $872.287K $3.072M $-2.686M -307.884% $-0.7 $-2.369M

Balance Statement

Period Cash & Short-term Total Assets Total Liabilities Total Equity
Q1-2026 $1.66M ▲ $10.038M ▲ $6.611M ▲ $3.621M ▲
Q4-2025 $1.02M ▼ $8.25M ▼ $5.436M ▲ $2.996M ▼
Q3-2025 $2.807M ▲ $9.585M ▲ $4.641M ▲ $5.114M ▲
Q2-2025 $2.242M ▼ $8.684M ▼ $4.481M ▼ $4.366M ▼
Q1-2025 $6.415M $13.779M $5.596M $8.329M

Cash Flow Statement

Period Net Income Cash From Operations Cash From Investing Cash From Financing Net Change Free Cash Flow
Q1-2026 $-2.983M ▲ $-2.847M ▼ $-70.4K ▲ $3.558M ▲ $640.196K ▲ $-2.917M ▼
Q4-2025 $-3.103M ▼ $-2.21M ▲ $-208.517K ▼ $601.997K ▼ $-1.787M ▼ $-2.418M ▲
Q3-2025 $-2.551M ▼ $-2.755M ▼ $-14.385K ▼ $3.322M ▲ $564.903K ▲ $-2.77M ▼
Q2-2025 $-2.249M ▲ $-2.325M ▲ $-8.936K ▼ $631.744K ▲ $-1.747M ▲ $-2.334M ▲
Q1-2025 $-2.695M $-2.387M $0 $42.45K $-2.315M $-2.387M

Revenue by Products

Product Q1-2025Q2-2025Q3-2025Q4-2025
Other Sales
Other Sales
 $0 ▲$0 ▲$0 ▲$0 ▲

Five-Year Company Overview

Income Statement

Income Statement The company is essentially still pre-revenue, with no meaningful sales reported over the past several years. Operating results show recurring losses, which is typical for an early-stage medical technology firm still investing in product development and commercialization. Earnings per share look very weak and volatile, but this is largely driven by repeated reverse stock splits and a very small base of business rather than a sudden shift in operations. Overall, the income statement tells the story of a company still in build-out mode, not yet in a steady commercial phase.

Balance Sheet

Balance Sheet The balance sheet is very light: assets are small, equity is thin, and there is effectively no debt. Cash has moved up and down over the years but remains limited, underlining that the company does not have a large financial cushion. The lack of debt reduces financial pressure from interest payments, but the modest level of assets and equity also suggests that the company is financially fragile and will likely depend on external funding to support growth and ongoing development.

Cash Flow

Cash Flow Cash flow from operations has been consistently negative, reflecting the fact that the business is spending more on development, staff, and overhead than it brings in from customers. Free cash flow is also negative, though the company is not spending heavily on physical equipment or facilities. This pattern is typical for a small, research-driven healthcare company but implies a continued need for fresh capital until meaningful revenue ramps up.

Competitive Edge

Competitive Edge Intelligent Bio Solutions is trying to carve out a distinct niche in the drug testing and diagnostics market with its fingerprint-based and sweat-based testing systems. Compared with traditional urine and blood testing, its approach is more convenient, more hygienic, and harder to tamper with, which is a clear selling point. It has built a growing portfolio of patents around its fingerprint drug screening cartridge and related components, which helps protect its technology. However, it is competing against much larger, well-known diagnostics companies that already dominate lab-based and rapid testing, so market education, regulatory approvals, and customer adoption remain major hurdles. The company’s small size and limited resources make execution risk high, even though its offering is differentiated.

Innovation and R&D

Innovation and R&D Innovation is the clear center of gravity for this company. Its commercial fingerprint drug testing solution uses sweat from fingerprints to detect recent drug use quickly and non-invasively, which is an inventive twist on a mature testing market. Beyond that, the saliva-based biosensor platform in development could be even more transformative if it works as intended, with fast results, low-cost printable components, and the potential to detect a wide range of health markers from saliva. Recent development milestones show technical progress, particularly around speed and sensitivity, but the platform is still early-stage. Clinical validation, regulatory clearance, and proof that it can be produced and adopted at scale are all ahead, and will require time, capital, and sustained R&D work.

Summary

Overall, Intelligent Bio Solutions is a very early-stage, highly innovative healthcare technology company with a tiny financial footprint and no meaningful revenue so far. Its core fingerprint drug testing system and emerging saliva biosensor platform are clearly differentiated and supported by growing intellectual property, which could give it a defensible position if adoption accelerates. At the same time, the company runs ongoing losses, has limited assets and cash, and is operating in a competitive, heavily regulated diagnostics market. Its future hinges on successfully obtaining regulatory clearances (particularly in the U.S.), converting its technology into reliable commercial sales, and securing sufficient funding along the way. The upside is closely tied to execution on these fronts, while financial and regulatory risks remain significant.

NEWS

November 20, 2025 · 8:30 AM UTC

Intelligent Bio Solutions to Participate in Noble Capital Markets' 21st Annual Emerging Growth Equity Conference on December 2-3, 2025

Read more

November 20, 2025 · 8:30 AM UTC

Intelligent Bio Solutions to Participate in Noble Capital Markets' 21st Annual Emerging Growth Equity Conference on December 2-3, 2025

Read more

November 12, 2025 · 8:30 AM UTC

Intelligent Bio Solutions Reports Fiscal 2026 First Quarter Financial Results and Operational Highlights, Delivering Record Revenue Growth

Read more

November 4, 2025 · 8:30 AM UTC

Intelligent Bio Solutions Expects to Report Record Fiscal First Quarter 2026 Revenue of Over $1 Million, an Increase of Approximately 32% Sequentially and 28% Year-Over-Year

Read more

October 30, 2025 · 8:30 AM UTC

Intelligent Bio Solutions Secures 33 New Customer Accounts in the Fiscal 2026 First Quarter, Showing Strong Year-Over-Year Growth and Increasing Total Active Accounts to 480

Read more